product Name：Ormetoprim
  • Rofenaid; 2,4-Diamino-5-(4,5-dimethoxy-2-methylbenzyl)pyrimidin; 2,4-Diamino-5-(6-methylveratryl)pyrimidine; 2,4-Pyrimidinediamine, 5-((4,5-dimethoxy-2-methylphenyl)methyl)-; NSC 95072; Ormetoprima; Ormetoprima [INN-Spanish]; Ormetoprime; Ormetoprime [INN-French]; Ormetoprimum; Ormetoprimum [INN-Latin]; Ormetorprim; Ro 5-9754; UNII-M3EFS94984; component of Rofenaid; Pyrimidine, 2,4-diamino-5-(6-methylveratryl)-; 5-(4,5-dimethoxy-2-methylbenzyl)pyrimidine-2,4-diamine; 5-(2,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine; 5-(4,5-dimethoxy-2-methylbenzyl)-2,4-diaminopyrimidine
  • 6981-18-6
  • 230-246-6
  • C14H18N4O3
  • 290.3177
  • InChI=1/C14H18N4O3/c1-19-10-6-12(21-3)11(20-2)5-8(10)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
  • Ormetoprim 6981-18-6
  • 1.252g/cm3
  • 535.302°C at 760 mmHg
  • 1.609
  • 277.541°C
  • 0mmHg at 25°C